13^th World Conference on Human Genomics and Genomic Medicine August 10-11, 2020 Dubai, UAE

Track 1: Human Genomics and Proteomics

Identifying and characterizing all common sequence variants in the human genome has changed our understanding of segregating diversity, population genetics and vulnerability to disease. Single Nucleotide polymorphisms, (SNPs) historically thought to be th dominant source of sequence variation while certain sequence variants, such as microscopically recognized sequence duplication and deletion, is identified.

• Genome Sequencing
• Genome Engineering
• Proteogenomics
• Protein Interactions
• Next Generation Sequencing

Track 2: Advances in Human Genome

Over the past decade there are many advances in genomic technologies, enabling biologists to explore the genetics for research opportunities. One  of the most exciting development in fields has been in genome sequencing assembly, where  researchers can now produce assemblies of genomes for the species they select.

• Human Genome Project
• International Hap Map Project
• Genomic Sequences
• Comparative Genomics

Track 3: Genetic Disorders and Diseases

A genetic disorder is a condition caused by a deviation in the DNA sequence away from the regular sequence, in whole or in part. Genetic abnormalities may be initiated tpdue  mutation in one gene or in more than one gene or due to environmental factors or due to chromosomal damages.

• Single – Gene Disorders
• Gene and Complex Disorders
• Chromosomal Disorders

Track 4: Human Genome and Mapping

Human Genome Project originally aimed at mapping nucleotides found in a human haploid reference genome. Each individual's genome is unique; gene mapping the human genome requires sequencing and then linking them together to produce a full sequence for each chromosome. The human genome is therefore a mosaic which is not represented by one person. 

• Genomic Maps
• Chromosome Mapping
• DNA Sequencing
• Human Genome

Track 5: Pharmacogenomics in Drug Discovery

Pharmacogenomics is the study of genome's function in responding to drugs. It is mixture of the genomics and pharmacology. Pharmacogenomics analyzes  how an individual's genetic makeup influences his / her response to drugs. It deals with the effect of genetic variation acquired and inherited on drug reaction in patients by attributing gene expression or single-nucleotide polymorphisms with pharmacokinetics (drug intake, delivery, metabolism, and elimination) and pharmacodynamic. For certain cases the term pharmacogenomicsis used interchangeably with pharmacogenetics.

• Pharmacometrics
• Target based Drug Discovery
• Reserve Pharmacology
• Pharmacokinetic aspects

Track 6: Oncogenomics- Genomic Approach to Cancer

Oncogenomics is a subfield of the genomics that characterizes the cancer related genes. Cancer is a genetic disease induced by accumulation of DNAmutations and epigenetic modifications that contribute to unrestrained cell proliferation and development of neoplasms. The aim of oncogenomics is to discover new genes for  oncogenes or tumor suppressors that can provide new insights into cancer identification,predict outcomes of clinical cancer and new targets for cancer treatment.The success of targeted cancer therapies like Gleevec, Herceptin, and Avastin has increased hopes that oncogenomics will elucidate new targets for cancer care.

• Medical Oncology
• Surgical Oncology
• Cancer Therapy
• Comparative oncogenomics

Track 7: Neurogenomics- Approach to Gene Expression in Brain

Gene expression is one of the key molecular mechanisms that control the differentiation, growth and functioning of cells and tissues. Gene expression of the brain varies over the various phases of life. Early development sees the most important levels of expression, with the rate of gene expression being the highest
during fetal development. This is because of the fast growth of neurons in the embryo.

• Human Brain
• Gene Expression Profiling
• Imaging studies and optical mapping
• Genetic analysis of Brain disorders

Track 8: Microbial Genomics and Infectious Diseases

Differences in the sequence and structure of genomes from members ofa microbial community represent the mutation, recombination, and selection composite effects. With the growing availability of genome sequences, these effects have been better characterized and exploited in order to understand the nature and evolution of microbes and viruses and their often intimate relationships with humans.

• Pathogenesis and Symbiosis
• Genetic and Evolutionary Computing
• Genome Mapping and Genomics in Microbes

Track 9: Computational Genomics and Bioinformatics

Bioinformatics is sharing the origins of computational genomics withothers. Computational genomics analyzes vast databases of biological data, such as genetic sequences, populations of cells or to discover new biologies.

• Analytical methods
• Mathematical modeling
• Statistical Genetics
• Bioinformatics Techniques

Track 10: Nutrigenomics- Control for Chronic Diseases

Nutrigenomics studies the genome effect of nutrients, and the responseto diet from human genetic makeup. Active dietary molecules and human genetics are two major factors that control the development ofchronic diseases like cancer, cardiovascular disorders, diabetics, hypertension and obesity. Adequate nutrient intake protects us from developing chronic diseases. The nutrients should be kept in the optimal balance between the total oxidation status and the genome's total antioxidant response to maintain a degree of equilibrium between these two variables.

• Antioxidant
• Proteome
• Transcription factor
• Single Nucleotide Polymorphisms

Track 11: Molecular Genetics and Genomic Medicine

Molecular genetics is a genetic subfield that uses genetic screens to determine genetic structure and/or function 
within an organism's genome using an investigative approach. The research area focuses on the integration of numerous biology subfields like cell biology, molecular biology,biochemistry, and biotechnology. Genomic Medicine  and Healthcare course was planned for healthcare professionals including medical physicians,general practitioners, allied health professionals, nurses, genetic counselors and others with equivalent undergraduate degrees or comparable professional qualifications and background experience.

• Molecular Biology
• Genomic Medicine
• Molecular Diagnostic Methods
• Genomic Analysis

Track 12: Biomarkers and Genomic Medicine

Biomarkers are the observable predictor showing the particularperson's existence, or quantity or extent of the disorder. Existing genomics and biotechnology applications provide assurance of biomarker production to guess the livelihood of disease in an individual ,enable initial disease identification and improve diagnostic classification for better individualized improvement.

• MicroRNAs
• Biomarker Discovery
• Biomarkers into Clinical Medicine
• Genomic Variations

Track 13: Implications of Genomics on Public Health

Public health practice aims to recognize the causes of the disease,anticipate and avoid it where possible, and or else detect it early and efficiently treat it so as to mitigate morbidity, disability and death.The making of effective epidemiological methods is to look at disease over the past years and its contribution  to the risk factors and providing basic strategies for disease prevention and health promotion.

• Personalized Prevention
• Health Screening
• Public Health Practice
• Health Protection

The National Human Genome Research Institute defines human genomic medicine as an emerging medical discipline that involves using genomic information about an individual as part of their clinical care. Genomic medicine is a type of a precision medicine in which genomics, epigenomics and other related data is used to accurately aid in individual disease diagnosis. Genomic medicine increasingly being used not only for research purpose but also in clinical applications. Genomic Medicine gaining momentum with expanding applications ranging from risk assessment and diagnosis in healthy individuals to genome-based treatment for patients with complicated disorders.

Genomic Medicine Market: Segmentation

Based on application, the global genomic medicine market is segmented into the following:

• Oncology
• Cardiology
• Pediatrics
• Endocrinology
• Rare Genetic Disorders
• Respiratory Medicine
• Infectious Diseases
• Other applications

Based on end use, the global genomic medicine market is segmented into the following:

• Hospitals
• Clinics
• Academic Institutions

The Growth of Human Genome Market over the years:

The worldwide genomics showcase size was evaluated at USD 15.48 billion out of 2018 and is foreseen to extend at a CAGR of 8.6% over the conjecture time frame. The development of genomic information pool due research exercises has empowered doctors, scholars, and patients to additionally examine the hereditary inclination to specific infections. Clinical use of this information pool is required to assume a significant job in changing the human services framework regarding the arrangement of increasingly exact, compelling, and dependable illness the board arrangements.

In spite of the fact that the clinical use of genomic information is at a beginning stage in present, the social insurance and research network are making endeavours for compelling reconciliation of hereditary data into clinical work processes. A few clinical focuses, for example, Stanford Health Care and other malignant growth investigate focuses, have started utilizing the accessible genomic data to devise customized treatment system. This, thusly, helps in crossing over any barrier between translational research and clinical determination and treatment. The worldwide hereditary testing market since 2015 and the market is ready to develop by USD 4.86 billion during 2020-2024 at a CAGR of over 12% during the conjecture time frame.

Market study of Human Genetics:

The Genetic Market is increasing day by day .Each Continents are having their share in the growing market of human genomics. The most contributed continent in this regard is Middle East which contributes about 31% and the second contributed country is Asia Pacific which contributes about 30%. Them it is followed by USA which con tributes only 22%in the market .The least contribution is made by Europe which is 17%only.

The Future of Human Genome:

The worldwide market of human hereditary qualities holds the monstrous potential to flood. Qualities are the keys that open the complexities of how the body capacities, which can help in the advancement of better diagnostics and viable treatment for the lethal issue, for example, malignant growth and AIDs or clutters, for example, Alzheimer and Parkinson that have constrained treatment choices. The ascent deprived to meet the medicinal prerequisites of patients is required to provoke development for the overall human hereditary market. The development of the patient pool is probably going to reinforce the market. It is seen that the human hereditary market is probably going to blast in the coming years.

The ascent in awareness of quality treatment and increment in the commonness of quality treatment is noted to heighten the human hereditary qualities showcase development. Innovative work focuses and criminological labs are very good quality clients of the human hereditary qualities methods. Governments, over the globe, making robust speculations, and increment in wrongdoing cases are causes that are probably going to make the market pattern upwards. The ascent deprived for progressively compelling and non-intrusive treatment and urgent need to rapidly explain criminal cases are can enlarge the market development. Nonetheless, the absence of prepared experts can block the human hereditary qualities showcase development

    List of Hospitals, Research Centers and Labs     

India will Launch its 1^st  Human Genome Mapping Project  

India will launch its first human genome mapping project by October, a move that will help researchers get closer to developing effective therapies for treating diseases such as cancer. In the first phase of the initiative called the Genome India project, the genomic data of 10,000 Indians will be catalogued. The Department of Biotechnology (DBT) has initiated the project.